# CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

> **NCT00576225** · PHASE3 · WITHDRAWN · sponsor: **CTI BioPharma**

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** CT-2103/carboplatin
- **DRUG:** paclitaxel/carboplatin

## Key facts

- **NCT ID:** NCT00576225
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-09
- **Primary completion:** 2010-04-05
- **Final completion:** 2010-04-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576225, "CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00576225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*